- Home
- TOVX vs RDHL Comparison
TOVX vs RDHL Comparison
Compare TOVX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- RDHL
- Stock Information
- Founded
- TOVX 2001
- RDHL 2009
- Country
- TOVX United States
- RDHL Israel
- Employees
- TOVX N/A
- RDHL N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- RDHL Health Care
- Exchange
- TOVX Nasdaq
- RDHL Nasdaq
- Market Cap
- TOVX 4.5M
- RDHL 3.9M
- IPO Year
- TOVX 2006
- RDHL N/A
- Fundamental
- Price
- TOVX $0.41
- RDHL $1.50
- Analyst Decision
- TOVX Hold
- RDHL
- Analyst Count
- TOVX 1
- RDHL 0
- Target Price
- TOVX N/A
- RDHL N/A
- AVG Volume (30 Days)
- TOVX 1.0M
- RDHL 88.3K
- Earning Date
- TOVX 11-11-2025
- RDHL 09-05-2025
- Dividend Yield
- TOVX N/A
- RDHL N/A
- EPS Growth
- TOVX N/A
- RDHL N/A
- EPS
- TOVX N/A
- RDHL N/A
- Revenue
- TOVX N/A
- RDHL $9,550,000.00
- Revenue This Year
- TOVX N/A
- RDHL $381.91
- Revenue Next Year
- TOVX N/A
- RDHL N/A
- P/E Ratio
- TOVX N/A
- RDHL N/A
- Revenue Growth
- TOVX N/A
- RDHL 157.62
- 52 Week Low
- TOVX $0.37
- RDHL $1.06
- 52 Week High
- TOVX $4.29
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- TOVX 46.90
- RDHL 53.60
- Support Level
- TOVX $0.38
- RDHL $1.22
- Resistance Level
- TOVX $0.45
- RDHL $1.60
- Average True Range (ATR)
- TOVX 0.02
- RDHL 0.08
- MACD
- TOVX 0.00
- RDHL 0.04
- Stochastic Oscillator
- TOVX 46.71
- RDHL 73.68
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.